Phoenix Biotech Acquisition in a proxy filing seeks shareholder approval for a deadline extension in monthly increments from July until Oct. 3, if necessary.
The SPAC in December mutually terminated a $136 million deal with Intrinsic Medicine.
Phoenix Biotech raised $155 million in an October 2021 IPO with plans to target healthcare or healthcare related industries in the United States and Europe, especially life sciences companies. Read more.
